US FDA Approves Third Indication of Darolutamide for Patients with Advanced Prostate Cancer

Orion’s collaboration partner Bayer announced that the US FDA has approved the oral androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy for use in patients with metastatic castration-sensitive prostate cancer.